Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform On … Continue reading Brickell Biotech (NASDAQ: BBI) Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update